{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-070826","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.251846+00:00","generated_at":"2026-06-14T01:52:04.209393+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cellectar delays WM pivotal trial top-line data to H2 2023; pediatric glioma trial to start Q3","bullets":["Top-line data from WM CLOVER-WaM trial delayed to H2 2023; 2024 product launch still targeted.","All 49 sites now active; enrollment accelerated after initial delays from site contracting and regulatory responses.","Plans to initiate Phase 1b study in pediatric high-grade gliomas in Q3 2023, supported by $2M NCI grant.","Iopofosine I 131 showed 100% ORR, 83.3% major response rate in Phase 2a WM study (6 patients).","Fast Track Designation allows 6-month FDA review; platform expands to alpha-emitter, siRNA, and peptide payloads."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-070826","json":"https://secwatch.observer/filing/0001104659-23-070826.json","markdown":"https://secwatch.observer/filing/0001104659-23-070826.md","text":"https://secwatch.observer/filing/0001104659-23-070826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/0001104659-23-070826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/tm2318538d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:52:04.209393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}